Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Failure patterns of cervical lymph nodes in metastases of unknown origin according to target volume.

Kim DY, Heo DS, Keam B, Ock CY, Ahn SH, Kim JH, Jung KC, Kim JH, Wu HG.

Radiat Oncol J. 2020 Mar;38(1):18-25. doi: 10.3857/roj.2020.00108. Epub 2020 Mar 30.

2.

Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma.

Ha H, Keam B, Ock CY, Kim TM, Kim JH, Chung EJ, Kwon SK, Ahn SH, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2020 Mar 30. doi: 10.3904/kjim.2019.104. [Epub ahead of print]

3.

Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses.

Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, Li D, Calvo R, Dashnyam M, Singh A, Guerin T, White J, Ravichandran S, Kumar P, Talsania K, Chen V, Ghebremedhin A, Karanam B, Bin Salam A, Amin R, Odzorig T, Aiken T, Nguyen V, Bian Y, Zarif JC, de Groot AE, Mehta M, Fan L, Hu X, Simeonov A, Pate N, Abu-Asab M, Ferrer M, Southall N, Ock CY, Zhao Y, Lopez H, Kozlov S, de Val N, Yates CC, Baljinnyam B, Marugan J, Rudloff U.

Sci Transl Med. 2020 Feb 12;12(530). pii: eaax6337. doi: 10.1126/scitranslmed.aax6337.

PMID:
32051227
4.

Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies.

Park C, Kim M, Kim MJ, Kim H, Ock CY, Keam B, Kim TM, Kim DW, Kim JI, Heo DS.

Mol Cancer Ther. 2020 Mar;19(3):937-944. doi: 10.1158/1535-7163.MCT-19-0457. Epub 2019 Dec 11.

PMID:
31826932
5.

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.

Park C, Keam B, Yoon SH, Ock CY, Choi SM, Kim M, Park YS, Kim TM, Oh DY, Kim DW, Kim YW, Heo DS, Bang YJ.

ESMO Open. 2019 Nov 28;4(6):e000575. doi: 10.1136/esmoopen-2019-000575. eCollection 2019.

6.

Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.

Koh J, Nam SK, Lee YW, Kim JW, Lee KW, Ock CY, Oh DY, Ahn SH, Kim HH, Kang KW, Kim WH, Lee HY, Lee HS.

Biomolecules. 2019 Nov 26;9(12). pii: E782. doi: 10.3390/biom9120782.

7.

Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.

Kim S, Jang JY, Koh J, Kwon D, Kim YA, Paeng JC, Ock CY, Keam B, Kim M, Kim TM, Heo DS, Chung DH, Jeon YK.

J Exp Clin Cancer Res. 2019 Nov 12;38(1):462. doi: 10.1186/s13046-019-1407-5.

8.

Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer.

Huh G, Ahn SH, Suk JG, Lee MH, Kim WS, Kwon SK, Ock CY, Keam B, Heo DS, Kim JH, Wu HG.

Jpn J Clin Oncol. 2020 Feb 17;50(2):185-192. doi: 10.1093/jjco/hyz158.

PMID:
31711185
9.

Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.

Keam B, Kang CK, Jun KI, Moon SM, Suh KJ, Lee DW, Ock CY, Kim M, Choi Y, Lim Y, Lee KH, Kim SH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Lee JS, Kim ES, Kim HB, Kim NJ, Kim YJ, Park WB, Oh MD.

Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print]

PMID:
31680143
10.

Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy.

Byun JM, Hong J, Yoon SS, Koh Y, Ock CY, Kim TM, Lee JH, Kim SH, Lee JO, Bang SM, Yhim HY, Bae SH, Mun YC, Oh D; Korean Thrombosis and Hemostasis Working Party of Korean Society of Hematology.

Thromb Res. 2019 Nov;183:131-135. doi: 10.1016/j.thromres.2019.10.002. Epub 2019 Oct 20.

PMID:
31677593
11.

Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.

Yoo C, Ryu YM, Kim SY, Kim J, Ock CY, Ryu MH, Kang YK.

Br J Cancer. 2019 Nov;121(10):819-826. doi: 10.1038/s41416-019-0596-1. Epub 2019 Oct 14.

PMID:
31607749
12.

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

Heo JY, Park C, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Kim SH, Kim YJ, Lee JS, Heo DS.

Thorac Cancer. 2019 Nov;10(11):2117-2123. doi: 10.1111/1759-7714.13195. Epub 2019 Sep 11.

13.

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.

Kim YJ, Keam B, Ock CY, Song S, Kim M, Kim SH, Kim KH, Kim JS, Kim TM, Kim DW, Lee JS, Heo DS.

Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.

PMID:
31494530
14.

High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Kim S, Nam SJ, Park C, Kwon D, Yim J, Song SG, Ock CY, Kim YA, Park SH, Kim TM, Jeon YK.

Oncoimmunology. 2019 Jun 10;8(9):e1626653. doi: 10.1080/2162402X.2019.1626653. eCollection 2019.

PMID:
31428525
15.

First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.

Kim R, Keam B, Hahn S, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Sep;20(5):331-338.e4. doi: 10.1016/j.cllc.2019.05.009. Epub 2019 May 11.

PMID:
31164319
16.

Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.

Yoo SH, Keam B, Ock CY, Kim S, Han B, Kim JW, Lee KW, Jeon YK, Jung KC, Chung EJ, Kwon SK, Ahn SH, Sung MW, Heo DS.

Sci Rep. 2019 May 22;9(1):7680. doi: 10.1038/s41598-019-44206-2.

17.

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

Choi M, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Jul;20(4):e442-e451. doi: 10.1016/j.cllc.2019.03.005. Epub 2019 Mar 29.

PMID:
31010639
18.

Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.

Kim WJ, Dho YS, Ock CY, Kim JW, Choi SH, Lee ST, Kim IH, Kim TM, Park CK.

J Neurooncol. 2019 Jun;143(2):321-328. doi: 10.1007/s11060-019-03167-2. Epub 2019 Apr 13.

PMID:
30982199
19.

Interleukin 1 Up-regulates MicroRNA 135b to Promote Inflammation-Associated Gastric Carcinogenesis in Mice.

Han TS, Voon DC, Oshima H, Nakayama M, Echizen K, Sakai E, Yong ZWE, Murakami K, Yu L, Minamoto T, Ock CY, Jenkins BJ, Kim SJ, Yang HK, Oshima M.

Gastroenterology. 2019 Mar;156(4):1140-1155.e4. doi: 10.1053/j.gastro.2018.11.059. Epub 2018 Nov 30.

PMID:
30508510
20.

Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.

Ock CY, Seo H, Kim DY, Min BJ, Park Y, Cheong HS, Kim HL, Song EY, Kim I, Yoon SS, Kim JH, Koh Y.

Leuk Lymphoma. 2019 Jul;60(7):1775-1781. doi: 10.1080/10428194.2018.1542142. Epub 2018 Dec 3.

PMID:
30507323
21.

Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?

Yoo SH, Ock CY, Keam B, Park SJ, Kim TM, Kim JH, Jeon YK, Chung EJ, Kwon SK, Hah JH, Kwon TK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2019 Nov;34(6):1313-1323. doi: 10.3904/kjim.2017.397. Epub 2018 Nov 16.

22.

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.

Kim SH, Ryu H, Ock CY, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Bang SM, Kim JH, Lee JS, Ahn JB, Kim KJ, Rha SY.

Int J Mol Sci. 2018 Oct 15;19(10). pii: E3164. doi: 10.3390/ijms19103164.

23.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2019 Sep;34(5):1116-1124. doi: 10.3904/kjim.2018.011. Epub 2018 Jun 29.

24.

Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.

Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW, Yoo CW, Lee GK, Han JY.

J Thorac Oncol. 2018 May;13(5):636-648. doi: 10.1016/j.jtho.2018.01.008. Epub 2018 Jan 31.

25.

Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer.

Sakai E, Nakayama M, Oshima H, Kouyama Y, Niida A, Fujii S, Ochiai A, Nakayama KI, Mimori K, Suzuki Y, Hong CP, Ock CY, Kim SJ, Oshima M.

Cancer Res. 2018 Mar 1;78(5):1334-1346. doi: 10.1158/0008-5472.CAN-17-3303. Epub 2017 Dec 27.

26.

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2017 Jun 16;8(58):97920-97927. doi: 10.18632/oncotarget.18542. eCollection 2017 Nov 17.

27.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

28.

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):670-680. doi: 10.4143/crt.2017.051. Epub 2017 Jul 3.

29.

Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.

Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS.

Oncotarget. 2017 Apr 18;8(16):26356-26367. doi: 10.18632/oncotarget.15465.

30.

Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice.

Bae JS, Park JM, Lee J, Oh BC, Jang SH, Lee YB, Han YM, Ock CY, Cha JY, Hahm KB.

Metabolism. 2017 Jan;66:32-44. doi: 10.1016/j.metabol.2016.10.002. Epub 2016 Oct 11.

PMID:
27923447
31.

Genetic ablation or pharmacologic inhibition of autophagy mitigated NSAID-associated gastric damages.

Ock CY, Park JM, Han YM, Jeong M, Kim MY, Lee HJ, Hahm KB.

J Mol Med (Berl). 2017 Apr;95(4):405-416. doi: 10.1007/s00109-016-1491-3. Epub 2016 Dec 2.

PMID:
27913816
32.

Mild form of Guillain-Barré syndrome in a patient with primary Epstein-Barr virus infection.

Kim SY, Choe KW, Park S, Yoon D, Ock CY, Hong SW, Heo JY.

Korean J Intern Med. 2016 Nov;31(6):1191-1193. Epub 2016 Feb 2. Review. No abstract available.

33.

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.

Kim R, Keam B, Kwon D, Ock CY, Kim M, Kim TM, Kim HJ, Jeon YK, Park IK, Kang CH, Kim DW, Kim YT, Heo DS.

World J Gastroenterol. 2016 Oct 7;22(37):8389-8397.

34.

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.

An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DVT, Oh DY, Bang YJ.

Ann Oncol. 2017 Jan 1;28(1):110-115. doi: 10.1093/annonc/mdw442.

35.

Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.

Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, Oh DY.

Gastric Cancer. 2017 Mar;20(2):254-262. doi: 10.1007/s10120-016-0613-5. Epub 2016 May 5.

PMID:
27147244
36.

Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer.

Park S, Park S, Lee SH, Suh B, Ock CY, Keam B, Kim TM, Kim DW, Kim YW, Heo DS.

Cancer Biomark. 2016;16(3):425-33. doi: 10.3233/CBM-160581.

PMID:
27062699
37.

Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.

Ock CY, Keam B, Kim TM, Han DH, Won TB, Lee SH, Hah JH, Kwon TK, Kim DW, Kim DY, Rhee CS, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2016 May;31(3):570-8. doi: 10.3904/kjim.2015.020. Epub 2016 Mar 15.

38.

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2016 Mar 29;7(13):15901-14. doi: 10.18632/oncotarget.7431.

39.

Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study.

Kim R, Ock CY, Keam B, Kim TM, Kim JH, Paeng JC, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.

BMC Cancer. 2016 Feb 17;16:116. doi: 10.1186/s12885-016-2147-y.

40.

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.

Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Clin Cancer Res. 2016 May 1;22(9):2261-70. doi: 10.1158/1078-0432.CCR-15-2834. Epub 2016 Jan 27.

41.

The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.

Ock CY, Nam AR, Bang JH, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY.

Am J Cancer Res. 2015 Oct 15;5(11):3376-88. eCollection 2015.

42.

Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.

Ock CY, Nam AR, Bang JH, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY.

Gastric Cancer. 2017 Jan;20(1):164-174. doi: 10.1007/s10120-015-0583-z. Epub 2015 Dec 17.

PMID:
26681196
43.

Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.

Ock CY, Son B, Keam B, Lee SY, Moon J, Kwak H, Kim S, Kim TM, Jeon YK, Kwon SK, Hah JH, Lee SH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.

J Cancer Res Clin Oncol. 2016 Apr;142(4):873-83. doi: 10.1007/s00432-015-2083-2. Epub 2015 Dec 16.

PMID:
26677030
44.

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.

Kim R, Hahn S, Shin J, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS.

Cancer Res Treat. 2016 Jul;48(3):907-16. doi: 10.4143/crt.2015.359. Epub 2015 Nov 17. Review.

45.

Exploiting Language Models to Classify Events from Twitter.

Vo DT, Hai VT, Ock CY.

Comput Intell Neurosci. 2015;2015:401024. doi: 10.1155/2015/401024. Epub 2015 Sep 14.

46.

A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin.

Kim SY, Kim SJ, Yoon D, Hong SW, Park S, Ock CY.

Tuberc Respir Dis (Seoul). 2015 Jul;78(3):281-5. doi: 10.4046/trd.2015.78.3.281. Epub 2015 Jun 30.

47.

Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.

Ock CY, Keam B, Lim Y, Kim TM, Lee SH, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.

Head Neck. 2016 Feb;38(2):277-84. doi: 10.1002/hed.23891. Epub 2015 Jun 18.

PMID:
26104823
48.

Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications.

Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY.

Gastric Cancer. 2016 Apr;19(2):421-430. doi: 10.1007/s10120-015-0504-1. Epub 2015 May 23.

PMID:
26002144
49.

Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer.

Ock CY, Oh DY, Lee J, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ.

Gastric Cancer. 2016 Apr;19(2):597-606. doi: 10.1007/s10120-015-0481-4. Epub 2015 Mar 8.

PMID:
25749718
50.

Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.

Ock CY, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Kim WH, Bang YJ, Oh DY.

Clin Cancer Res. 2015 Jun 1;21(11):2520-9. doi: 10.1158/1078-0432.CCR-14-2659. Epub 2015 Feb 23.

Supplemental Content

Support Center